# Hikma Pharmaceuticals USA, Inc.: Dopamine Hydrochloride Injection shortage update (unavailable from this maker)

**Score:** 70/100

| Field | Value |
|---|---|
| Manufacturer | Hikma Pharmaceuticals USA, Inc. |
| Drug | Dopamine Hydrochloride Injection |
| Dosage form | Injection |
| Therapeutic category | Cardiovascular |
| Status | Current |
| Stage | Shortage revised (availability or dates changed) |
| Availability | Unavailable |
| Reason | Demand increase for the drug |
| Presentations affected | 2 |
| Package NDCs | 0143-9254-25, 0143-9252-25 |
| Manufacturer supply note | Product temporarily on backorder. Additional lots will be available in the February 2027 timeframe. |
| First posted | 2017-11-06 |
| Updated | 2026-10-14 |

## Why this score
- Shortage details just changed.
- Unavailable from this manufacturer.
- Sterile injectable: hospital and 503B demand.

Source: openFDA drug shortages endpoint (U.S. Food and Drug Administration drug shortage list) (https://dps.fda.gov/drugshortages). Last refreshed: 2026-11-04T06:10:12.565Z.
From the openFDA drug shortages endpoint, which mirrors the FDA drug shortage list and can lag it by days. Availability and recovery notes are the manufacturer's own statements to FDA. Company and product level only. Verify with FDA and the manufacturer before acting.